The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)
Status:
Terminated
Trial end date:
2017-03-31
Target enrollment:
Participant gender:
Summary
This is a proof of concept trial using ranolazine, a medication, in patients with known
Coronary Artery Disease and reduced left ventricular function, EF < 40%. We propose that
ranolazine therapy will result in demonstrative improvements in cardiac function that can be
objectively assessed using the parameters measured with CPET. We propose that demonstrative
improvement in CPET parameters on ranolazine will translate into improved patient outcomes
for this patient population.
Phase:
N/A
Details
Lead Sponsor:
Cardiovascular Institute of the South Clinical Research Corporation